Lexicon Pharmaceuticals (LXRX) News
NASDAQ: LXRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LXRX news summary
We found 8 recent headlines mentioning Lexicon Pharmaceuticals (LXRX): 0 in the past week and 6 in the past 30 days, most often from GlobeNewswire, Seeking Alpha, Nasdaq. LXRX is making an outsized move today, down 8.38% at $1.53, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London", was published by GlobeNewswire on Nov 11, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Lexicon Pharmaceuticals headlines
- Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in LondonTHE WOODLANDS, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced that Company management will…GlobeNewswire
- Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Tops Revenue EstimatesLexicon (LXRX) delivered earnings and revenue surprises of +50.00% and +3.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqLXRX, TGTX
- Lexicon Pharmaceuticals GAAP EPS of -$0.03 beats by $0.03, revenue of $11.3M beats by $7.16MSeeking Alpha
- Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical UpdatesPhase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027GlobeNewswire
- Lexicon Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha
- Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its…GlobeNewswire
- Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study…GlobeNewswire
- Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy -- -- Second preclinical study shows inhibitory effects of…GlobeNewswire